High Blood Pressure: New Injection Hope
- A clinical trial reveals that a twice-yearly injection could offer a considerable and lasting reduction in high blood pressure.
- The KARDIA-2 global trial, led by Queen Mary University of London researchers, included 663 participants whose high blood pressure was not well-controlled by their current medications.
- The study demonstrated that adding zilebesiran to existing medication more effectively lowered blood pressure than medication alone. This could significantly benefit the one in three adults in the...
Discover how a groundbreaking new high blood pressure injection, zilebesiran, is showing remarkable promise in clinical trials. This innovative treatment offers a twice-yearly injection, possibly revolutionizing the management of hypertension and providing a lasting reduction in high blood pressure for those whose condition isn’t well-controlled. Adding the zilebesiran high blood pressure injection to existing medication proved more effective than medication alone, according to a recent study. Learn about how this could significantly benefit the one in three adults in the UK affected by hypertension. News Directory 3 brings you the latest on this advancement and its potential to lower the risk of heart attacks and strokes. This novel treatment targets a protein in the liver to relax blood vessels.What are the next steps for this promising new treatment? Discover what’s next and the potential long-term benefits.
New High Blood Pressure Injection Shows Promising Results
Updated May 31, 2024
A clinical trial reveals that a twice-yearly injection could offer a considerable and lasting reduction in high blood pressure. The findings, involving an investigational therapeutic called zilebesiran, were published in JAMA.
The KARDIA-2 global trial, led by Queen Mary University of London researchers, included 663 participants whose high blood pressure was not well-controlled by their current medications. Patients received the high blood pressure injection, zilebesiran, in addition to their standard treatments.
The study demonstrated that adding zilebesiran to existing medication more effectively lowered blood pressure than medication alone. This could significantly benefit the one in three adults in the United Kingdom affected by hypertension, a condition that, if untreated, raises the risk of heart attacks, strokes, and death.
Dr. Manish Saxena, Clinical co-Director at Queen Mary University of London, led the UK study and co-authored the publication.
Zilebesiran uses RNA interference to target a specific protein (angiotensinogen) in the liver, which helps relax blood vessels and lower blood pressure. The high blood pressure injection is administered under the skin.
“Hypertension is a global health concern as blood pressure control rates remain poor and is a leading cause of heart attacks and strokes,” Saxena said. “This study demonstrates the efficacy and safety of zilebesiran, when added to commonly used first line blood pressure lowering drugs. The novelty of this treatment is its long duration; giving just one injection every six months could help millions of patients to better manage their condition.”
What’s next
Zilebesiran will undergo further Phase 2 trials (KARDIA-3) to assess its potential for treating individuals with established cardiovascular disease or those at high risk. A large global outcomes study is planned to evaluate its impact on reducing cardiovascular events, strokes, and cardiovascular death.